JBCHEPHARM at 20x FY23 EPS is a much safer and a better buy than a conventional FMCG Player like HINDUNILVR with no significant reinvestment moat and single digit earnings growth.
The difference here is that JB can still reinvest bulk of its cash flows at a similar/higher ROIIC.
The cash compounding machine JBCHEPHARM does 42% ROCE ex cash, EBITDA Margins at 27.4%, I as an investor would be happy if they maintain margins in mid 20s.
— Saket Reddy (@saketreddy) June 15, 2021
FY21 EPS of Rs. 58, you are getting a company growing at > 20% since the last 5 years at < 1 PEG and 26x TTM Earnings. pic.twitter.com/5u4u0C5MpK
More from Saket Reddy
SAREGAMA
Today's closing is a monthly close and this is done & dusted, we now have a solid monthly close above the 10 year supply zone.
If the stock has broken out from a 10 year supply zone & a 20 year peak, surely something would've changed!
Do study the industry structure! https://t.co/zA3qztFzon
Today's closing is a monthly close and this is done & dusted, we now have a solid monthly close above the 10 year supply zone.
If the stock has broken out from a 10 year supply zone & a 20 year peak, surely something would've changed!
Do study the industry structure! https://t.co/zA3qztFzon
SAREGAMA at a very important juncture now on the monthly chart considering today's close is also a monthly close.
— Saket Reddy (@saketreddy) May 31, 2021
Nearing a breakout from over a 10 year supply zone! https://t.co/qpsSn3obrE pic.twitter.com/1xTmB6WvhK